In the Margins

Valeant names hedge fund partner to board

October 26, 2015

By Forbes

Valeant Pharmaceuticals has named Mason Morfit, a partner at activist hedge fund ValueAct Capital, to its board of directors. Morfit previously served on the embattled specialty drugmaker's board from 2007 to 2014; ValueAct is one of Valeant's largest shareholders. Read the original story from Forbes

 

 

Most Read

A Seat at the Table
Invesco Funds board finalizes succession plans

The Invesco Funds board will name Christopher Wilson vice chairman at its June meeting, making him the heir apparent to long-serving independent Chair Bruce Crockett. Crockett ...

Top of the Agenda - Compensation
Fund board comp moves up, as industry keeps changing

Analyzing mutual fund director compensation data is getting increasingly difficult as consolidation reshapes the mid-sized to large end of the market and a reduction in stand-alone ...